A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma

Prather, Kiana Y.; O’Neal, Christen M.; Westrup, Alison M.; Tullos, Hurtis J.; Hughes, Kendall L.; Conner, Andrew K.; Glenn, Chad A.; Battiste, James

doi:10.1093/noajnl/vdac008

Cited by 16 publications

(13 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…104 Glioma is the most common malignant intracranial tumor. 105 Wnt/β-catenin pathway is the main signaling pathway for ionizing radiation-induced glioblastoma cell invasion. Inhibition and stimulation of the Wnt/β-catenin pathway can affect the cell cycle, thereby reducing the proliferation and survival of U87 glioma cells.…”

Section: Wnt Signaling Pathway and Msmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway

Li,

Wang,

Zhang

2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

As an important signaling pathway in multicellular eukaryotes, the Wnt signaling pathway participates in a variety of physiological processes. Recent studies have confirmed that the Wnt signaling pathway plays an important role in neurological disorders such as stroke, Alzheimer's disease, and Parkinson's disease. The regulation of Wnt signaling by natural compounds in herbal medicines and nutraceuticals has emerged as a potential strategy for the development of new drugs for neurological disorders. Purpose: The aim of this review is to evaluate the latest research results on the efficacy of natural compounds derived from herbs and nutraceuticals in the prevention and treatment of neurological disorders by regulating the Wnt pathway in vivo and in vitro. A manual and electronic search was performed for English articles available from PubMed, Web of Science, and ScienceDirect from the January 2010 to February 2023. Keywords used for the search engines were "natural products,″ "plant derived products,″ "Wnt+ clinical trials,″ and "Wnt+,″ and/or paired with "natural products″/″plant derived products", and "neurological disorders." A total of 22 articles were enrolled in this review, and a variety of natural compounds from herbal medicine and nutritional foods have been shown to exert therapeutic effects on neurological disorders through the Wnt pathway, including curcumin, resveratrol, and querctrin, etc. These natural products possess antioxidant, anti-inflammatory, and angiogenic properties, confer neurovascular unit and blood−brain barrier integrity protection, and affect neural stem cell differentiation, synaptic formation, and neurogenesis, to play a therapeutic role in neurological disorders. In various in vivo and in vitro studies and clinical trials, these natural compounds have been shown to be safe and tolerable with few adverse effects. Natural compounds may serve a therapeutic role in neurological disorders by regulating the Wnt pathway. This summary of the research progress of natural compounds targeting the Wnt pathway may provide new insights for the treatment of neurological disorders and potential targets for the development of new drugs.

show abstract

Section: Wnt Signaling Pathway and Msmentioning

confidence: 99%

“…Glioma is the most common malignant intracranial tumor . Wnt/β-catenin pathway is the main signaling pathway for ionizing radiation-induced glioblastoma cell invasion.…”

Section: Wnt Signaling Pathway and Neurological Disordersmentioning

confidence: 99%

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway

Li,

Wang,

Zhang

2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

show abstract

“…Dynamic TAC patterns are helpful for diagnostic and prognostic purposes, particularly in distinguishing progression from TRC. 44 Bevacizumab is an antiangiogenic chemotherapy drug targeting circulating vascular endothelial growth factor and lowering cerebrovascular permeability. It is an adjunctive therapy in recurrent HGGs and significantly reduces contrast enhancement, underestimating residual tumor evaluation.…”

Section: Monitoring Treatment Response To Newer Drugs In Recurrent Hg...mentioning

confidence: 99%

Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know

Soni¹,

Ora²,

Jena³

et al. 2023

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

PET with amino acid tracers provides additional insight beyond MR imaging into the biology of gliomas that can be used for initial diagnosis, delineation of tumor margins, planning of surgical and radiation therapy, assessment of residual tumor, and evaluation of posttreatment response. Hybrid PET MR imaging allows the simultaneous acquisition of various PET and MR imaging parameters in a single investigation with reduced scanning time and improved anatomic localization. This review aimed to provide neuroradiologists with a concise overview of the various amino acid tracers and a practical understanding of the clinical applications of amino acid PET MR imaging in glioma management. Future perspectives in newer advances, novel radiotracers, radiomics, and cost-effectiveness are also outlined.ABBREVIATIONS: AAT ¼ amino acid tracer; AA ¼ amino acid; ASCT ¼ alanine-serine-cysteine transporter; BTV ¼ biologic tumor volume; GBM ¼ glioblas-G liomas represent approximately 80% of malignant brain tumors, with an annual incidence rate of 5.6 cases per 100,000 individuals worldwide. Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, representing approximately 50% of all gliomas and 16% of all brain tumors. 1 Depending on the size and extent of these tumors, the standard of care for newly diagnosed GBMs usually includes maximal surgical resection followed by radiation and chemotherapy. Despite substantial development in managing high-grade gliomas (HGGs), the median survival is ,15 months, with 1-and 5-year survival rates of 40% and 5.5%, respectively. 2 Imaging is crucial for diagnosing, guiding biopsy, surgical planning, and distinguishing treatment-related changes (TRC) from recurrence in glioma management. MR imaging is the primary imaging technique; however, it lacks specificity to distinguish between viable neoplastic tissue and tumor-free areas.Advanced MR imaging techniques such as PWI, DWI, DTI, MRS, and molecular imaging (PET) facilitate visualization and quantification of different metabolic processes and improve overall diagnostic performance in brain tumors. Hybrid PET MR imaging with novel radiotracers provides a noninvasive, simultaneous assessment of brain tumor morphologic, functional, metabolic, and molecular parameters. 3,4 This review aimed to provide neuroradiologists with a concise overview of the various amino acid tracers (AATs) and a practical understanding of the clinical applications of amino acid (AA) PET MR imaging in glioma management. We will review the current literature regarding AA-PET MR imaging in glioma treatment and discuss its role in the initial diagnosis, delineation of tumor margin, planning of radiation therapy, assessment of residual tumor, and evaluation of treatment response. We will sum up with future perspectives on newer advances, novel radiotracers, radiomics, and cost-effectiveness. RadiopharmaceuticalsThe Joint European Association of Nuclear Medicine (EANM)/ European Association of Neuro-Oncology (EANO)/Response Assessment in Neuro-Oncology (RA...

show abstract

“…It has been shown that the amino acid uptake is increased in tumors at progression but not in brain areas of treatment-related changes [26]. For example, 18 F-fluoroethyltyrosine ( 18 F-FET) could facilitate the detection of PsP because 18 F-FET uptake is significantly lower in patients with PsP than in those with true progression [27].…”

Section: Neuroimagingmentioning

confidence: 99%

Liquid Biopsy in Glioblastoma

Ronvaux

Riva

Coosemans

et al. 2022

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

show abstract

A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma

Cited by 16 publications

References 51 publications

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway

Therapeutic Potential of Natural Compounds from Herbs and Nutraceuticals in Alleviating Neurological Disorders: Targeting the Wnt Signaling Pathway

Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know

Liquid Biopsy in Glioblastoma

Contact Info

Product

Resources

About